Wanbury Share Price

Wanbury Limited, together with its subsidiaries, is an Indian pharmaceutical company primarily engaged in the manufacturing of active pharmaceutical ingredients (APIs) and finished formulations. The company offers a basket of over 13 API products and is recognized as the largest manufacturer of Metformin globally. It also provides formulations for gynecology, orthopedics, anti-diabetic, nutraceuticals, antibiotics, and other therapeutic segments. Wanbury share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Wanbury stock price often mirrors shifts in API demand, generic medicine consumption, and investor views on the pharmaceutical sector’s growth prospects. Factors such as the pace of new API product launches, competitive intensity from domestic and international players, raw material cost inflation, and changing regulatory frameworks influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Wanbury stock price movements.

Wanbury live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Wanbury live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Wanbury share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Wanbury Limited Company Fundamentals

a. Company Background

Wanbury Limited is an Indian pharmaceutical company engaged in the manufacturing of active pharmaceutical ingredients (APIs) and finished formulations in India and internationally. It was incorporated in 1988 and is headquartered in Navi Mumbai, India. The company’s registered office is located at BSEL Tech Park, Navi Mumbai, Maharashtra. Wanbury was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company established its first plant in 1992 in Tarapur for manufacturing APIs, acquired a plant of Brij Chemicals Pvt Ltd at Patalganga in 1995, and entered into a strategic partnership in 1996. Wanbury is recognized as the largest manufacturer of Metformin, a leading anti-diabetic API, with over 8,500 tons per year production capacity. The company has filed over 27 Drug Master Files (DMFs) and has two approved product patents to its credit. It operates within India’s growing pharmaceutical industry, driven by rising healthcare demand, increasing generic medicine consumption, and government initiatives promoting domestic API manufacturing.

b. Product Lines

• Active Pharmaceutical Ingredients (APIs) for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, anti-inflammatory medicines, and high-potent anaesthetic APIs

• Finished formulations for gynecology, orthopedics, haematinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner segments

• Metformin (largest manufacturer globally with over 8,500 tons per year)

• Sertraline Hydrochloride and Carvedilol (patented products)

c. Company Revenue Model

• Primary revenue from the manufacture and sale of active pharmaceutical ingredients (APIs) to domestic and international generic pharmaceutical companies

• Revenue from the sale of finished formulations in the domestic market

• Revenue from exports to international markets including the United States, Europe, and other regions

• Income from contract manufacturing and toll manufacturing services

• Revenue from the sale of pharmaceutical intermediates and specialty chemicals

d. Geographic Presence

• Registered office located in Navi Mumbai, Maharashtra, India

• Manufacturing facilities located at Tarapur (established 1992) and Patalganga (acquired 1995)

• Strong domestic presence with pan-India formulation distribution

• International presence through exports to global markets including the United States, Europe, and other regions

• Clients include leading global generic players including Apotex, Teva, Mylan, and McNeil

• Focus on expanding international footprint in regulated markets

e. Key Milestones

• 1988: Incorporated as Pearl Organics Limited

• 1992: Established first plant in Tarapur for manufacturing APIs

• 1995: Acquired plant of Brij Chemicals Pvt Ltd at Patalganga

• 1996: Entered into a strategic partnership

• 2004: Name changed from Pearl Organics Limited to Wanbury Limited

• 2023: Bagiaburu Iron Ore Mine started operations in December 2023

• 2025: Reported first profit after quarters of losses in Q2 FY26

• 2026: Commenced commercial production of high-potent anaesthetic API at Tanuku facility

f. Industry Perspective: Pharmaceutical Industry in India

Wanbury operates in the global and Indian pharmaceutical industry. India’s pharmaceutical industry has evolved into a globally integrated and policy-supported system, ranking third globally by volume and 11th by value, with more than 3,000 companies and 10,500 manufacturing units. The domestic pharmaceutical market, valued at USD 60 billion in 2025, is projected to reach USD 130 billion by 2030. According to Mordor Intelligence, the India pharmaceutical market stands at USD 66.66 billion in 2025 and is forecast to reach USD 88.86 billion by 2030, advancing at a 5.92% CAGR. According to Bain & Co, the Indian Pharmaceutical market stood at Rs. 4,71,295 crore (US$ 55 billion) in 2025 and is expected to grow to Rs. 10,28,280-11,13,970 crore (US$ 120-130 billion) by 2030. In FY25, the sector’s annual turnover reached Rs. 4.72 lakh crore, with exports growing at a CAGR of 7% over the last decade (FY15 to FY25). India is the largest global supplier of generic medicines, accounting for around 20% of global supply, manufacturing about 60,000 generic brands across 60 therapeutic categories. There are about 500 API manufacturers in India, accounting for nearly 8% of the global API industry. In 2024-25, pharmaceutical exports stood at USD 30.5 billion, a nearly 16-fold increase from USD 1.9 billion in 2000-01. Chronic diseases, policy incentives, and steady export demand give the market a balanced twin-engine of domestic consumption and international sales. Key growth drivers include government PLI schemes targeting 11 bulk-drug lines, expansion of health insurance penetration (only 35% of Indians carry health insurance), and the shift from acute to chronic therapies. However, the industry faces challenges including high dependence on Chinese APIs for complex molecules (currently 80% of import volume), drug-price controls under NLEM compressing margins, and regulatory approval delays for novel molecules. The industry outlook remains positive, supported by sustained domestic demand, export growth, and government initiatives promoting API self-reliance.

Wanbury Limited Stock Market Presence: Listings & Index Representation

Wanbury Limited is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol WANBURY and on the Bombay Stock Exchange (BSE) with the scrip code 524212. The ISIN number of the company’s equity shares is INE107F01022. The face value of the equity shares is ₹10 per share. Its listing on both exchanges ensures that the Wanbury share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Wanbury Limited is included in indices such as the BSE 500, BSE AllCap, and BSE SmallCap. These index participations signal the company’s relevance within market categories that attract both active and passive investment flows. Being represented in multiple indices enhances the visibility and liquidity of the Wanbury stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Wanbury in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Wanbury Limited Stock Performance and Share Price History

The Wanbury price has displayed significant volatility over the past decade, shaped by the company’s financial performance, pharmaceutical sector cycles, and broader market trends. The Wanbury share price delivered a strong positive return of 71.1% in 2021, 150.1% in 2020, and 157.2% in 2023, reflecting robust recovery and strong demand for pharmaceutical products. The Wanbury share price also delivered positive returns of 127.0% in 2024. However, the Wanbury share price experienced negative returns of 41.5% in 2022, 23.5% in 2025, and 9.3% in 2019. Over the 10-year period ending April 2026, the Wanbury share price has delivered a cumulative return of approximately 17.3%, underperforming the BSE Healthcare index which delivered 10.7% over the same period. The Wanbury share price reached a 52-week high of ₹329.70 and a 52-week low of ₹161.50, indicating a wide trading range and substantial price fluctuations. As of April 6, 2026, the Wanbury share price was trading at approximately ₹226.61 on the NSE and ₹229.05 on the BSE, with a market capitalisation of approximately ₹800 crore.

The Wanbury stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 1194.16% year-on-year rise in net profit to ₹15.76 crore for the December 2025 quarter, the Wanbury stock price showed a positive reaction. The Wanbury share price has shown a pattern of strong positive momentum following strong earnings reports, while periods of weak financial results or market consolidation have contributed to declines in the Wanbury stock price. The Wanbury share price delivered a 1-year total return of approximately -8.2% as of April 2026, underperforming the BSE Healthcare index which returned 2.5% over the same period. The Wanbury share price has shown a YTD return of 0.0% as of April 6, 2026, while the 1-month return was -9.4% and the 3-month return was 0.0%. The Wanbury share price has been influenced by corporate developments including the commercial production of a high-potent anaesthetic API at its Tanuku facility in January 2026. The Wanbury share price has shown average weekly volatility of approximately 0.6% to 1.2% over different periods, which is lower than the industry average. Based on data, the beta for Wanbury has been recorded at 1.53 for the long-term range, indicating that the stock has exhibited higher volatility than the broader market over extended periods. The Wanbury share price has a 10-year aggregate net profit of approximately ₹207.43 crore, a 10-year aggregate EBITDA of approximately ₹184.98 crore, and a 10-year aggregate CFO of approximately ₹300.59 crore. Comprehending these patterns in the Wanbury price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Wanbury stock price movements illustrate how industry fundamentals, demand cycles, raw material cost pressures, and investor expectations converge in market pricing.

Wanbury Limited Investor Relevance and Role in Portfolio

Wanbury holds a distinctive position for portfolio investors who seek exposure to the Indian pharmaceutical sector with a focus on API manufacturing. The company’s diversified product portfolio across Metformin, other APIs, and finished formulations aligns it with investment strategies that value both domestic pharmaceutical demand and global export opportunities. The Wanbury share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor API demand indicators and regulatory approval metrics when evaluating allocation decisions.

Institutional stakeholders play a moderate role in Wanbury’s ownership profile. The promoters held 43.07% of the company as of December 2025, showing a stable trend. Mutual fund holders of Wanbury include various institutional investors. Foreign Institutional Investors (FIIs) hold 0.72% of the company as of December 2025. Domestic Institutional Investors (DIIs) hold 0.00% of the company. Public investors hold approximately 41.28% of the company. Overall institutional holding in the company stands at approximately 0.72% as of December 2025.

Based on data, the beta for Wanbury has been recorded at 1.53 for the long-term range (calculated on monthly ticks over 4 years), indicating that the stock has exhibited higher volatility than the broader market over extended periods. In the short-term daily analysis, beta values of -0.388 for the one-month range and 0.0365 for the three-month range show mixed sensitivity to market fluctuations. Weekly data reveals a beta of 0.669 over one year and 0.910 over two years, indicating a rise in volatility over longer durations. The 2-week beta over a two-year period stands at 1.35, reflecting high responsiveness, while the monthly beta over two years reaches 1.61. The mean values across these periods range from 67.07 to 155.33, with standard deviations from 1.62 to 17.52, indicating higher price variability in longer periods. Other sources report a beta of 1.31 to 1.65, confirming higher sensitivity to market fluctuations. The Wanbury share price has shown periods of heightened responsiveness to sector-specific news, quarterly earnings releases, and raw material price movements. The Wanbury share price reflects that the company’s position in the pharmaceutical sector may result in moderate to high price fluctuations. The Wanbury stock price is thus viewed as a growth opportunity within a portfolio context with varying volatility characteristics depending on the time frame.

Wanbury Limited Sectoral Relevance and Peer Positioning

The sector relevance of Wanbury is anchored in its role within the broader Indian pharmaceutical and API manufacturing industry, where it competes with other diversified pharmaceutical companies. As part of this industry, the company’s strategic positioning connects API manufacturing, finished formulations, and contract manufacturing that serve multiple therapeutic segments. Competitors in adjacent segments include companies such as Sun Pharmaceutical Industries Limited, Divi’s Laboratories Limited, Torrent Pharmaceuticals Limited, Cipla Limited, and other API manufacturers including Aarti Drugs Ltd., Aarti Pharmalabs Ltd., and Anuh Pharma Ltd. Larger players such as Sun Pharma and Divi’s Laboratories have larger scales and global footprints, though Wanbury competes directly in the Metformin API segment, where it holds the position of the largest manufacturer globally. Firms with parallels in either API manufacturing scale or product complexity are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Wanbury P/E ratio tend to reflect narrative shifts in earnings expectations and investor confidence relative to these peers. The Wanbury P/E ratio stood at approximately 12.4 as of April 2026, a 72% discount to its peers’ median range of 44.74 times. The Wanbury earnings history over the past five years has shown a pattern of significant volatility. Revenue increased from ₹392.52 crore in FY2021 to ₹599.51 crore in FY2025, representing a growth of approximately 53% over five years. Net profit showed a turnaround from a loss of ₹12.61 crore in FY2021 to a profit of ₹30.53 crore in FY2025, with a peak of ₹81.47 crore in FY2022. The 10-year aggregate net profit of the company stands at approximately ₹207.43 crore. Quarterly net profit for the December 2025 quarter rose 1194.16% year-on-year to ₹15.76 crore, reflecting a strong recovery. The Wanbury EPS narrative has followed a similar pattern of volatility. EPS (TTM) has been recorded at approximately ₹19.2 as of April 2026, with basic EPS of ₹6.18 in March 2025, ₹2.44 in September 2024, and ₹4.52 in December 2025. The Wanbury market cap has shown a pattern of fluctuation over the past decade. Wanbury market cap increased from approximately ₹500 crore in earlier years to approximately ₹800 crore as of April 2026. This directional behaviour in valuation multiples demonstrates how market expectations around growth prospects and earnings durability influence broader assessment of the Wanbury share price within its industry context. The Wanbury stock price remains a key barometer for the API manufacturing segment.

Over the last ten years, Wanbury market cap has shown a pattern of significant fluctuation. The company’s market cap increased from lower levels in earlier years to approximately ₹800 crore as of April 2026. The market cap has shown a 10-year aggregate net profit of approximately ₹207.43 crore, a 10-year aggregate EBITDA of approximately ₹184.98 crore, and a 10-year aggregate CFO of approximately ₹300.59 crore. The current market cap stands at approximately ₹800 crore, having ranged between lower levels and its current value over the past decade.

Wanbury earnings, in terms of net profit, have exhibited a pattern of high volatility over the past decade. Net profit increased from a loss of ₹12.61 crore in FY2021 to a profit of ₹81.47 crore in FY2022, to a loss of ₹10.4 crore in FY2023, to a profit of ₹30.4 crore in FY2024, and to a profit of ₹30.53 crore in FY2025. The 10-year aggregate net profit of the company stands at approximately ₹207.43 crore. Quarterly net profit for the December 2025 quarter rose 1194.16% year-on-year to ₹15.76 crore, reflecting a strong recovery. Revenue increased from ₹392.52 crore in FY2021 to ₹599.51 crore in FY2025.

Wanbury EPS history over the past decade has shown a pattern of high volatility. EPS (TTM) has been recorded at approximately ₹19.2 as of April 2026. Basic EPS stood at ₹6.18 in March 2025, ₹2.44 in September 2024, ₹0.38 in December 2024, and ₹4.52 in December 2025. This volatile EPS trajectory reflects the impact of raw material price fluctuations, competitive intensity, and the cyclical nature of the pharmaceutical industry.

Wanbury P/E ratio history has shown a pattern of variation, fluctuating between moderate and elevated levels over the past decade. The P/E ratio stood at approximately 12.4 as of April 2026, a 72% discount to its peers’ median range of 44.74 times. Other sources report P/E ratios of 16.90, 17.50, and 20.94 over different periods. This valuation discount reflects that investor expectations remain anchored to the company’s earnings recovery trajectory and market position in the API manufacturing segment.

Summary

Wanbury is an Indian pharmaceutical company listed on both the NSE and BSE, where the Wanbury share price reflects API demand cycles, pharmaceutical sector trends, and competitive dynamics within the healthcare industry. Its representation in stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare consumption patterns. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in the Indian pharmaceutical market.